Name: Lizhong Liu

Position: Professor

E-mail: liulz@szu.edu.cn

Personal Statement:

Professor Liu received his Ph.D. from The Chinese Academy of Medical Sciences & Peking Union Medical College in 2005, and then joined the Department of Medicine and Therapeutics of Chinses University of Hong Kong for postdoctoral training. In 2012, he joined the Shenzhen University Medical School as an associate professor and was awarded Shenzhen peacock high-level talents at the same time.

Professor Liu is mainly engaged in the research of the pathogenesis of diabetes, with special focus on the relationship between lipid metabolism disorder and the occurrence and development of lung cancer. Using biochemistry and cell biology as the main research methods, to explore the molecular mechanism of the dynamic changes of cytoskeleton structure and vesicular transport of fatty acids and glucose transporters. The projects he has led come from the Natural Science Foundation of China, the Natural Science Foundation of Guangdong, and the Shenzhen Basic Research Project. Dr. Liu has published many papers in high impact academic journals such as Cell Death Dis., Mol Cancer., Theranostics, J Exp Clin Cancer Res., etc.

Research Interests:

Insulin signal transmission

Glycolipid metabolism

Ferroptosis of tumor cells

Research Projects:

1. National Natural Science Foundation of China (81570784), 01/01/2016 to 31/12/2019, ￥690,000.

2. National Natural Science Foundation of China (82072584), 01/01/2020 to 31/12/2024, ￥660,000.

3. Natural Science Foundation of Guangdong (2025A1515012228), 01/01/2025 to 31/12/2027, ￥100,000.

4. Shenzhen Basic Research Project (JCYJ20240813143509012), 01/11/2024 to 31/11/2027, ￥300,000.

5. Shenzhen Basic Research Project (JCYZ20220531102215035), 01/10/2022 to 31/10/2025, ￥300,000.

6. Shenzhen Basic Research Project (20200813175957001), 01/01/2021 to 31/10/2022, ￥300,000.

7. Shenzhen Basic Research Project (JCYJ20150324141711688), 01/08/2015 to 31/08/2022, ￥300,000.

8. Shenzhen Peacock Research Project (827-000003), 01/09/2013 to 31/12/2015, ￥3,000,000.

Selected Peer-reviewed Publications:

1. Liu LZ, Wang BW, Zhang R, Wu ZS, Huang YX, Zhang XY, Zhou JY, Yi JB, Shen J, Li MY, Dong M,The activated CD36-Src axis promotes lung adenocarcinoma cell proliferation and actin remodeling-involved metastasis in high-fat environment. Cell Death Dis. 2023, 14(8): 548.

2. Li MY, Wang MH, Dong M, Wu ZS, Zhang R, Wang BW, Huang YX, Zhang XY, Zhou JY, Yi JB, Chen GG, Liu LZ*. Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis. iScience. 2023, 26(8): 107477.

3. Li MY, Liu LZ*, Dong M*. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. Mol Cancer. 2021 Jan 27;20(1):22. (Co-corresponding author)

4. Zhu B, Li MY, Lin Q, Liang Z, Xin Q, Wang M, He Z, Wang X, Wu X, Chen GG, Tong PCY, Zhang W, Liu LZ*. Lipid oversupply induces CD36 sarcolemmal translocation via dual modulation of PKCζ and TBC1D1: an early event prior to insulin resistance. Theranostics. 2020, 10(3):1332-1354.

5. Liu LZ, Wang M, Xin Q, Wang B, Chen GG, Li MY. The permissive role of TCTP in PM 2.5/NNK-induced epithelial-mesenchymal transition in lung cells. J Transl Med. 2020 Feb 11;18(1):66.